Coronavirus (COVID-19): visiting The Royal Marsden suspended

Coronavirus (COVID-19) latest: Visiting The Royal Marsden is still suspended, but we want to reassure our patients, their families and anyone worried about cancer during this difficult time that we are still delivering treatment - the hospital is open. Please see more information here about how we are keeping everyone safe.

Dr Susana Banerjee

Consultant Medical Oncologist, Clinical Research Lead Gynaecology Unit MBBS MA PhD FRCP

Specialism: Gynaecology

Available at: Chelsea, Sutton

Special interests:

  • Ovarian cancer
  • Advanced endometrial cancer
  • Recurrent cervical cancer
  • Rare gynaecological cancers
  • Targeted therapies


Dr Susana Banerjee (MBBS MA PhD FRCP) is a Consultant Medical Oncologist and Research Lead for the Gynaecology Unit at The Royal Marsden. She is also Reader in Women’s Cancers at the Institute of Cancer Research. Dr Banerjee specialises in ovarian cancer and the systemic treatment of endometrial and cervical cancers. 

Dr Banerjee graduated with a first class from St. John's College, University of Cambridge. She gained a PhD from the Institute of Cancer Research, University of London and completed specialist training at The Royal Marsden. 

Dr Banerjee has been involved in several national and international specialist groups including the National Cancer Research Institute (NCRI) Gynaecological Cancers Clinical Studies Group, European Organization for Research and Treatment of Cancer (EORTC) Executive Steering Committee for Gynaecological Cancers, and ESGO (European Society of Gynaecological Oncology) Congress Faculty. Dr Susana Banerjee serves on the European Society of Medical Oncology (ESMO) Executive Board. She was the Track Chair for Gynaecological Cancers at ESMO Congress 2018 and Scientific Co-Chair for ESMO Asia 2018. 

Dr Banerjee is an author of over 100 peer-reviewed publications and is actively involved in clinical trials and translational research. Dr Banerjee is UK Chief Investigator and Principal Investigator at The Royal Marsden for multiple national and international clinical trials. Her research interests include individualisation of patient treatment, targeted therapies (including PARP inhibitors) and rare gynaecological cancers.

Clinical units